α-1,4-linked D-glucopyranosyl residues. The molecular structure of these glucose derivatives, which approximates a truncated cone, bucket, or torus, generates a hydrophilic exterior surface and a nonpolar interior cavity. Cyclodextrins can interact with appropriately sized drug molecules to yield an inclusion complex. Smaldone's group proposed a cheap and simple synthesis of the CD-MOF-1 from natural products. They dissolved sugar (γ-cyclodextrin) and an alkali salt (KOH, KCl, potassium benzoate) in distilled bottled water and allowed 190 proof grain alcohol (Everclear) to vapor diffuse into the solution for a week. The synthesis resulted in a cubic (γ-CD)6 repeating motif with a pore size of approximately 1 nm. Subsequently, in 2017 Hartlieb et al. at Northwestern did further research with CD-MOF-1 involving the encapsulation of ibuprofen. The group studied different methods of loading the MOF with ibuprofen as well as performing related bioavailability studies on the ibuprofen-loaded MOF. They investigated two different methods of loading CD-MOF-1 with ibuprofen; crystallization using the potassium salt of ibuprofen as the alkali cation source for production of the MOF, and absorption and deprotonation of the free-acid of ibuprofen into the MOF. From there the group performed in vitro and in vivo studies to determine the applicability of CD-MOF-1 as a viable delivery method for ibuprofen and other NSAIDs. In vitro studies showed no toxicity or effect on cell viability up to 100 μM. In vivo studies in mice showed the same rapid uptake of ibuprofen as the ibuprofen potassium salt control sample with a peak plasma concentration observed within 20 minutes, and the cocrystal has the added benefit of double the half-life in blood plasma samples. The increase in half-life is due to CD-MOF-1 increasing the solubility of ibuprofen compared to the pure salt form. Since these developments many groups have done further research into drug delivery with water-soluble, biocompatible MOFs involving common over-the-counter drugs. In March 2018 Sara Rojas and her team published their research on drug incorporation and delivery with various biocompatible MOFs other than CD-MOF-1 through simulated cutaneous administration. The group studied the loading and release of ibuprofen (hydrophobic) and aspirin (hydrophilic) in three biocompatible MOFs (MIL-100(Fe), UiO-66(Zr), and MIL-127(Fe)). Under simulated cutaneous conditions (aqueous media at 37 °C) the six different combinations of drug-loaded MOFs fulfilled "the requirements to be used as topical drug delivery systems, such as released payload between 1 and 7 days" and delivering a therapeutic concentration of the drug of